FATE · Fate Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Redmile Group, LLC 10% Owner | ▼ Sell | Other | 12,884,277 Shares held | 4/20/2026 | View profile |
| Valamehr Bahram Chief R&D Officer | ▼ Sell | Open Market | 591,815 Shares held | 8/4/2026 | View profile |
| TAHL CINDY General Counsel and Secretary | ▼ Sell | Open Market | 589,355 Shares held | 8/4/2026 | View profile |
| Wolchko J Scott President and CEO | ▼ Sell | Open Market | 371,248 Shares held | 1/9/2024 | View profile |
| Bressi Jerome Charles See Remarks | ▲ Buy | Grant | 335,203 Shares held | 1/15/2025 | View profile |
| MENDLEIN JOHN Director | ▲ Buy | Option Exercise | 311,231 Shares held | 1/19/2023 | View profile |
| Yu-Waye Chu Senior VP Clinical Development | ▼ Sell | Open Market | 140,676 Shares held | 4/18/2023 | View profile |
| Mark Plavsic Chief Technical Officer | ▼ Sell | Open Market | 123,705 Shares held | 1/10/2023 | View profile |
| Edward J. Dulac III Chief Financial Officer | ▼ Sell | Open Market | 101,479 Shares held | 3/4/2024 | View profile |
| Adawi Kamal CFO and Corporate Secretary | ▲ Buy | Grant | 100,000 Shares held | 1/15/2026 | View profile |
| Brian T. Powl Chief Commercial Officer | ▼ Sell | Open Market | 41,146 Shares held | 7/5/2023 | View profile |
| William H. Rastetter Director | ▲ Buy | Option Exercise | 36,331 Shares held | 5/5/2026 | View profile |
| Robert S. Epstein Director | ▲ Buy | Option Exercise | 36,331 Shares held | 5/5/2026 | View profile |
| Lee Michael Stewart Director | ▲ Buy | Grant | 11,331 Shares held | 6/9/2022 | View profile |
| Robert Hershberg Director | ▲ Buy | Grant | 10,659 Shares held | 6/9/2022 | View profile |
| Agarwal Shefali Director | ▲ Buy | Grant | 10,490 Shares held | 6/9/2022 | View profile |
| Timothy Coughlin Director | ▲ Buy | Grant | 9,892 Shares held | 6/9/2022 | View profile |
| Jooss Karin Director | ▲ Buy | Grant | 9,848 Shares held | 6/9/2022 | View profile |
| Xu Yuan Director | ▼ Sell | Open Market | 8,669 Shares held | 8/6/2024 | View profile |
Transaction History
| TAHL CINDY | ▼ Sell | Open Market | 38,800 | $95K | 8/4/2026 |
| Valamehr Bahram | ▼ Sell | Open Market | 43,947 | $108K | 8/4/2026 |
| TAHL CINDY | ▼ Sell | Open Market | 25,590 | $48K | 5/20/2026 |
| Valamehr Bahram | ▼ Sell | Open Market | 28,946 | $54K | 5/20/2026 |
| TAHL CINDY | ▲ Buy | Option Exercise | 122,220 | $161K | 5/6/2026 |
| TAHL CINDY | ▲ Buy | Option Exercise | 44,444 | $47K | 5/6/2026 |
| William H. Rastetter | ▲ Buy | Option Exercise | 25,000 | $42K | 5/5/2026 |
| Robert S. Epstein | ▲ Buy | Option Exercise | 25,000 | $42K | 5/5/2026 |
| Redmile Group, LLC | ▼ Sell | Other | 8,977,624 | $0 | 4/20/2026 |
| Redmile Group, LLC | ▼ Sell | Other | 8,977,624 | $0 | 4/20/2026 |
| Valamehr Bahram | ▲ Buy | Grant | 335,000 | $0 | 1/15/2026 |
| TAHL CINDY | ▲ Buy | Grant | 100,000 | $0 | 1/15/2026 |
| Adawi Kamal | ▲ Buy | Grant | 25,000 | $0 | 1/15/2026 |
| TAHL CINDY | ▼ Sell | Open Market | 10,589 | $11K | 1/9/2026 |
| Valamehr Bahram | ▼ Sell | Open Market | 5,190 | $6K | 1/9/2026 |
| Adawi Kamal | ▲ Buy | Grant | 75,000 | $0 | 10/20/2025 |
| Valamehr Bahram | ▼ Sell | Open Market | 14,466 | $15K | 8/4/2025 |
| TAHL CINDY | ▼ Sell | Open Market | 9,037 | $10K | 8/4/2025 |
| Bressi Jerome Charles | ▲ Buy | Grant | 65,000 | $0 | 1/15/2025 |
| TAHL CINDY | ▲ Buy | Grant | 70,000 | $0 | 1/15/2025 |
| Bressi Jerome Charles | ▼ Sell | Open Market | 5,980 | $9K | 1/10/2025 |
| TAHL CINDY | ▼ Sell | Open Market | 5,654 | $9K | 1/10/2025 |
| Valamehr Bahram | ▼ Sell | Open Market | 8,705 | $13K | 1/10/2025 |
| Redmile Group, LLC | ▼ Sell | Open Market | 341,633 | $574K | 12/20/2024 |
| Redmile Group, LLC | ▲ Buy | Open Market | 397,964 | $669K | 12/20/2024 |
| Redmile Group, LLC | ▼ Sell | Other | 1,084,936 | $1.8M | 12/20/2024 |
| Redmile Group, LLC | ▼ Sell | Other | 1,084,936 | $1.8M | 12/20/2024 |
| Redmile Group, LLC | ▼ Sell | Other | 30,110 | — | 12/12/2024 |
| Xu Yuan | ▼ Sell | Open Market | 633 | $3K | 8/6/2024 |
| TAHL CINDY | ▲ Buy | Grant | 200,000 | $0 | 7/29/2024 |
| Valamehr Bahram | ▲ Buy | Grant | 200,000 | $0 | 7/29/2024 |
| Edward J. Dulac III | ▼ Sell | Open Market | 2,447 | $19K | 3/4/2024 |
| Edward J. Dulac III | ▼ Sell | Open Market | 1,849 | $9K | 1/29/2024 |
| Wolchko J Scott | ▼ Sell | Open Market | 14,391 | $63K | 1/9/2024 |
| Edward J. Dulac III | ▼ Sell | Open Market | 7,028 | $31K | 1/9/2024 |
| Valamehr Bahram | ▼ Sell | Open Market | 11,271 | $49K | 1/9/2024 |
| TAHL CINDY | ▼ Sell | Open Market | 10,874 | $48K | 1/9/2024 |
| Edward J. Dulac III | ▼ Sell | Open Market | 5,182 | $19K | 1/2/2024 |
| Redmile Group, LLC | ▲ Buy | Open Market | 44,630 | $166K | 12/26/2023 |
| Redmile Group, LLC | ▼ Sell | Other | 1,655,370 | $6.2M | 12/26/2023 |
| Redmile Group, LLC | ▼ Sell | Other | 1,655,370 | $6.2M | 12/26/2023 |
| Edward J. Dulac III | ▼ Sell | Open Market | 1,585 | $6K | 12/18/2023 |
| TAHL CINDY | ▼ Sell | Open Market | 24,363 | $58K | 11/9/2023 |
| Edward J. Dulac III | ▼ Sell | Open Market | 4,718 | $13K | 8/18/2023 |
| Xu Yuan | ▼ Sell | Open Market | 632 | $2K | 8/4/2023 |
| Brian T. Powl | ▼ Sell | Open Market | 3,854 | $19K | 7/5/2023 |
| Edward J. Dulac III | ▼ Sell | Open Market | 5,182 | $25K | 7/5/2023 |
| Xu Yuan | ▼ Sell | Open Market | 3,460 | $19K | 6/14/2023 |
| Redmile Group, LLC | ▲ Buy | Open Market | 256,639 | $1.6M | 4/21/2023 |
| Redmile Group, LLC | ▲ Buy | Open Market | 20,000 | $120K | 4/20/2023 |
| Yu-Waye Chu | ▼ Sell | Open Market | 2,317 | $15K | 4/18/2023 |
| Yu-Waye Chu | ▼ Sell | Open Market | 215 | $1K | 4/18/2023 |
| Redmile Group, LLC | ▲ Buy | Open Market | 25,700 | $154K | 4/14/2023 |
| Redmile Group, LLC | ▼ Sell | Other | 5,492,385 | $32.1M | 4/14/2023 |
| Redmile Group, LLC | ▼ Sell | Other | 5,492,385 | $32.1M | 4/14/2023 |
| Redmile Group, LLC | ▼ Sell | Open Market | 302,339 | $1.8M | 4/14/2023 |
| Redmile Group, LLC | ▼ Sell | Other | 167,205 | — | 4/13/2023 |
| MENDLEIN JOHN | ▲ Buy | Option Exercise | 28,461 | $39K | 1/19/2023 |
| MENDLEIN JOHN | ▲ Buy | Open Market | 36,631 | $199K | 1/13/2023 |
| Valamehr Bahram | ▲ Buy | Option Exercise | 423 | $580 | 1/12/2023 |
| MENDLEIN JOHN | ▲ Buy | Open Market | 88,048 | $499K | 1/11/2023 |
| Wolchko J Scott | ▼ Sell | Open Market | 45,907 | $241K | 1/10/2023 |
| Valamehr Bahram | ▼ Sell | Open Market | 10,917 | $57K | 1/10/2023 |
| TAHL CINDY | ▼ Sell | Open Market | 11,553 | $61K | 1/10/2023 |
| Edward J. Dulac III | ▼ Sell | Open Market | 7,331 | $38K | 1/10/2023 |
| Mark Plavsic | ▼ Sell | Open Market | 3,418 | $18K | 1/10/2023 |
| Yu-Waye Chu | ▼ Sell | Open Market | 7,825 | $41K | 1/10/2023 |
| Edward J. Dulac III | ▼ Sell | Open Market | 4,703 | $140K | 8/18/2022 |
| Edward J. Dulac III | ▼ Sell | Open Market | 432 | $13K | 8/18/2022 |
| Wolchko J Scott | ▲ Buy | Option Exercise | 6,246 | $17K | 7/22/2022 |
| Wolchko J Scott | ▼ Sell | Open Market | 2,703 | $88K | 7/22/2022 |
| Wolchko J Scott | ▼ Sell | Open Market | 620 | $21K | 7/22/2022 |
| Wolchko J Scott | ▼ Sell | Open Market | 2,923 | $92K | 7/22/2022 |
| Wolchko J Scott | ▲ Buy | Option Exercise | 30,000 | $81K | 7/21/2022 |
| Wolchko J Scott | ▼ Sell | Open Market | 19,171 | $634K | 7/21/2022 |
| Wolchko J Scott | ▼ Sell | Open Market | 10,829 | $352K | 7/21/2022 |
| Valamehr Bahram | ▲ Buy | Option Exercise | 17,158 | $47K | 7/7/2022 |
| Valamehr Bahram | ▼ Sell | Open Market | 17,158 | $519K | 7/7/2022 |
| Valamehr Bahram | ▲ Buy | Option Exercise | 2,000 | $10K | 7/6/2022 |
| Valamehr Bahram | ▲ Buy | Option Exercise | 5,842 | $16K | 7/6/2022 |
| Valamehr Bahram | ▼ Sell | Open Market | 7,842 | $236K | 7/6/2022 |
| Mark Plavsic | ▼ Sell | Open Market | 3,719 | $92K | 7/5/2022 |
| Brian T. Powl | ▲ Buy | Grant | 45,000 | $0 | 6/27/2022 |
| Timothy Coughlin | ▲ Buy | Grant | 8,650 | $0 | 6/9/2022 |
| Robert Hershberg | ▲ Buy | Grant | 8,650 | $0 | 6/9/2022 |
| Redmile Group, LLC | ▲ Buy | Grant | 8,650 | $0 | 6/9/2022 |
| Jooss Karin | ▲ Buy | Grant | 8,650 | $0 | 6/9/2022 |
| MENDLEIN JOHN | ▲ Buy | Grant | 8,650 | $0 | 6/9/2022 |
| Lee Michael Stewart | ▲ Buy | Grant | 8,650 | $0 | 6/9/2022 |
| Robert S. Epstein | ▲ Buy | Grant | 8,650 | $0 | 6/9/2022 |
| Agarwal Shefali | ▲ Buy | Grant | 8,650 | $0 | 6/9/2022 |
| Xu Yuan | ▲ Buy | Grant | 8,650 | $0 | 6/9/2022 |
| William H. Rastetter | ▲ Buy | Grant | 8,650 | $0 | 6/9/2022 |
| Agarwal Shefali | ▼ Sell | Open Market | 841 | $18K | 6/7/2022 |
| MENDLEIN JOHN | ▼ Sell | Open Market | 1,364 | $31K | 6/3/2022 |
| Robert Hershberg | ▼ Sell | Open Market | 672 | $15K | 6/3/2022 |
| Timothy Coughlin | ▼ Sell | Open Market | 1,439 | $33K | 6/3/2022 |
| Agarwal Shefali | ▼ Sell | Open Market | 807 | $18K | 6/3/2022 |
| Jooss Karin | ▼ Sell | Open Market | 1,483 | $34K | 6/3/2022 |
| TAHL CINDY | ▲ Buy | Option Exercise | 25,000 | $164K | 6/1/2022 |
| TAHL CINDY | ▼ Sell | Open Market | 25,000 | $574K | 6/1/2022 |
| Wolchko J Scott | ▲ Buy | Option Exercise | 10,000 | $27K | 4/22/2022 |
| Wolchko J Scott | ▼ Sell | Open Market | 838 | $29K | 4/22/2022 |
| Wolchko J Scott | ▼ Sell | Open Market | 9,162 | $316K | 4/22/2022 |
| Wolchko J Scott | ▲ Buy | Option Exercise | 30,000 | $81K | 4/21/2022 |
| Wolchko J Scott | ▼ Sell | Open Market | 22,715 | $785K | 4/21/2022 |
| Wolchko J Scott | ▼ Sell | Open Market | 4,062 | $145K | 4/21/2022 |
| Wolchko J Scott | ▼ Sell | Open Market | 2,220 | $81K | 4/21/2022 |
| Wolchko J Scott | ▼ Sell | Open Market | 1,003 | $38K | 4/21/2022 |
| Yu-Waye Chu | ▼ Sell | Open Market | 4,062 | $144K | 4/19/2022 |
| TAHL CINDY | ▲ Buy | Option Exercise | 5,567 | $36K | 4/1/2022 |
| TAHL CINDY | ▼ Sell | Open Market | 25,000 | $971K | 4/1/2022 |
| TAHL CINDY | ▲ Buy | Option Exercise | 19,433 | $94K | 4/1/2022 |
| Valamehr Bahram | ▲ Buy | Option Exercise | 25,000 | $68K | 3/14/2022 |
| Valamehr Bahram | ▼ Sell | Open Market | 3,067 | $97K | 3/14/2022 |
| Valamehr Bahram | ▼ Sell | Open Market | 2,195 | $71K | 3/14/2022 |
| Valamehr Bahram | ▼ Sell | Open Market | 100 | $3K | 3/14/2022 |
| Valamehr Bahram | ▼ Sell | Open Market | 16,678 | $506K | 3/14/2022 |
| Valamehr Bahram | ▼ Sell | Open Market | 2,960 | $99K | 3/14/2022 |
| MENDLEIN JOHN | ▲ Buy | Option Exercise | 31,562 | $51K | 3/10/2022 |
| MENDLEIN JOHN | ▼ Sell | Open Market | 12,069 | $428K | 3/10/2022 |
| MENDLEIN JOHN | ▼ Sell | Open Market | 19,493 | $677K | 3/10/2022 |
| TAHL CINDY | ▲ Buy | Grant | 33,302 | $0 | 1/25/2022 |
| Edward J. Dulac III | ▲ Buy | Grant | 33,302 | $0 | 1/25/2022 |
| Mark Plavsic | ▲ Buy | Grant | 33,302 | $0 | 1/25/2022 |
| Yu-Waye Chu | ▲ Buy | Grant | 33,302 | $0 | 1/25/2022 |
| Valamehr Bahram | ▲ Buy | Grant | 33,302 | $0 | 1/25/2022 |
| Wolchko J Scott | ▲ Buy | Option Exercise | 10,000 | $27K | 1/21/2022 |
| Wolchko J Scott | ▼ Sell | Open Market | 10,000 | $380K | 1/21/2022 |
| Wolchko J Scott | ▲ Buy | Option Exercise | 30,000 | $82K | 1/20/2022 |
| Wolchko J Scott | ▼ Sell | Open Market | 30,000 | $1.2M | 1/20/2022 |
| Wolchko J Scott | ▼ Sell | Open Market | 10,047 | $487K | 1/11/2022 |
| Wolchko J Scott | ▼ Sell | Open Market | 4,519 | $222K | 1/11/2022 |
| TAHL CINDY | ▼ Sell | Open Market | 4,883 | $237K | 1/11/2022 |
| TAHL CINDY | ▼ Sell | Open Market | 536 | $26K | 1/11/2022 |
| Valamehr Bahram | ▼ Sell | Open Market | 4,152 | $201K | 1/11/2022 |
| Valamehr Bahram | ▼ Sell | Open Market | 418 | $21K | 1/11/2022 |
| Edward J. Dulac III | ▼ Sell | Open Market | 1,380 | $67K | 1/11/2022 |
| Edward J. Dulac III | ▼ Sell | Open Market | 390 | $19K | 1/11/2022 |
| Yu-Waye Chu | ▼ Sell | Open Market | 3,547 | $172K | 1/11/2022 |
| Yu-Waye Chu | ▼ Sell | Open Market | 418 | $21K | 1/11/2022 |
| Wolchko J Scott | ▼ Sell | Open Market | 20,894 | $986K | 1/10/2022 |
| Wolchko J Scott | ▼ Sell | Open Market | 101 | $5K | 1/10/2022 |
| TAHL CINDY | ▼ Sell | Open Market | 7,095 | $329K | 1/10/2022 |
| Valamehr Bahram | ▼ Sell | Open Market | 5,245 | $243K | 1/10/2022 |
| Valamehr Bahram | ▼ Sell | Open Market | 351 | $17K | 1/10/2022 |
| Wolchko J Scott | ▼ Sell | Open Market | 13,161 | $610K | 1/10/2022 |
| TAHL CINDY | ▼ Sell | Open Market | 643 | $30K | 1/10/2022 |
| TAHL CINDY | ▲ Buy | Option Exercise | 50,000 | $328K | 1/3/2022 |
| TAHL CINDY | ▼ Sell | Open Market | 4,427 | $256K | 1/3/2022 |
| TAHL CINDY | ▼ Sell | Open Market | 16,900 | $994K | 1/3/2022 |
| TAHL CINDY | ▼ Sell | Open Market | 27,812 | $1.7M | 1/3/2022 |
| TAHL CINDY | ▼ Sell | Open Market | 861 | $52K | 1/3/2022 |
| Edward J. Dulac III | ▲ Buy | Option Exercise | 14,437 | $513K | 12/20/2021 |
| Edward J. Dulac III | ▼ Sell | Open Market | 15,977 | $959K | 12/20/2021 |
| Valamehr Bahram | ▲ Buy | Option Exercise | 25,000 | $68K | 12/13/2021 |
| Valamehr Bahram | ▼ Sell | Open Market | 2,100 | $96K | 12/13/2021 |
| Valamehr Bahram | ▼ Sell | Open Market | 7,018 | $328K | 12/13/2021 |
| Valamehr Bahram | ▼ Sell | Open Market | 6,564 | $313K | 12/13/2021 |
| Valamehr Bahram | ▼ Sell | Open Market | 7,718 | $376K | 12/13/2021 |
| Valamehr Bahram | ▼ Sell | Open Market | 1,600 | $79K | 12/13/2021 |
| Yu-Waye Chu | ▲ Buy | Option Exercise | 7,500 | $122K | 12/10/2021 |
| Yu-Waye Chu | ▼ Sell | Open Market | 2,097 | $103K | 12/10/2021 |
| Yu-Waye Chu | ▼ Sell | Open Market | 900 | $45K | 12/10/2021 |
| Yu-Waye Chu | ▼ Sell | Open Market | 1,045 | $53K | 12/10/2021 |
| Yu-Waye Chu | ▼ Sell | Open Market | 600 | $33K | 12/10/2021 |
| Yu-Waye Chu | ▼ Sell | Open Market | 5 | $278 | 12/10/2021 |
| Yu-Waye Chu | ▼ Sell | Open Market | 1,822 | $95K | 12/10/2021 |
| Yu-Waye Chu | ▼ Sell | Open Market | 1,031 | $55K | 12/10/2021 |
| Valamehr Bahram | ▲ Buy | Grant | 60,958 | $0 | 11/19/2021 |
| TAHL CINDY | ▲ Buy | Grant | 60,958 | $0 | 11/19/2021 |
| Mark Plavsic | ▲ Buy | Grant | 59,540 | $0 | 11/19/2021 |
| Edward J. Dulac III | ▲ Buy | Grant | 59,540 | $0 | 11/19/2021 |
| Yu-Waye Chu | ▲ Buy | Grant | 60,958 | $0 | 11/19/2021 |
| Wolchko J Scott | ▲ Buy | Grant | 86,475 | $0 | 11/19/2021 |
| Wolchko J Scott | ▲ Buy | Option Exercise | 20,000 | $54K | 11/18/2021 |
| Wolchko J Scott | ▼ Sell | Open Market | 20,000 | $1.1M | 11/18/2021 |
| Wolchko J Scott | ▲ Buy | Option Exercise | 10,000 | $27K | 10/22/2021 |
| Wolchko J Scott | ▲ Buy | Option Exercise | 4,846 | $23K | 10/22/2021 |
| Wolchko J Scott | ▲ Buy | Option Exercise | 15,154 | $41K | 10/22/2021 |
| Wolchko J Scott | ▼ Sell | Open Market | 30,000 | $1.8M | 10/22/2021 |
| Wolchko J Scott | ▲ Buy | Option Exercise | 30,000 | $82K | 10/21/2021 |
| Wolchko J Scott | ▼ Sell | Open Market | 14,765 | $895K | 10/21/2021 |
| Wolchko J Scott | ▼ Sell | Open Market | 15,235 | $911K | 10/21/2021 |
| TAHL CINDY | ▲ Buy | Option Exercise | 50,000 | $328K | 10/1/2021 |
| TAHL CINDY | ▼ Sell | Open Market | 16,312 | $947K | 10/1/2021 |
| TAHL CINDY | ▼ Sell | Open Market | 21,844 | $1.3M | 10/1/2021 |
| TAHL CINDY | ▼ Sell | Open Market | 11,844 | $707K | 10/1/2021 |
| Edward J. Dulac III | ▲ Buy | Option Exercise | 17,325 | $615K | 9/28/2021 |
| Edward J. Dulac III | ▼ Sell | Open Market | 19,460 | $1.2M | 9/28/2021 |
| Valamehr Bahram | ▲ Buy | Option Exercise | 25,000 | $68K | 9/13/2021 |
| Valamehr Bahram | ▼ Sell | Open Market | 15,809 | $1.0M | 9/13/2021 |
| Valamehr Bahram | ▼ Sell | Open Market | 8,391 | $561K | 9/13/2021 |
| Valamehr Bahram | ▼ Sell | Open Market | 800 | $54K | 9/13/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Fate Therapeutics Secures $15M CIRM Grant for Lupus Trial
Fate Therapeutics announced it received a $15 million grant from the California Institute for Regenerative Medicine to advance its Phase 2 RECLAIM-LN trial for lupus nephritis. This funding supports the development of the company's FT819 therapy. The news coincides with the stock trading near its 52-week low, providing a potential catalyst for the healthcare sector.
Fate Therapeutics Secures $15M CIRM Grant for Lupus Trial. Fate Therapeutics announced it received a $15 million grant from the California Institute for Regenerative Medicine to advance its Phase 2 RECLAIM-LN trial for lupus nephritis. This funding supports the development of the company's FT819 therapy. The news coincides with the stock trading near its 52-week low, providing a potential catalyst for the healthcare sector.